JP2015506972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506972A5 JP2015506972A5 JP2014556141A JP2014556141A JP2015506972A5 JP 2015506972 A5 JP2015506972 A5 JP 2015506972A5 JP 2014556141 A JP2014556141 A JP 2014556141A JP 2014556141 A JP2014556141 A JP 2014556141A JP 2015506972 A5 JP2015506972 A5 JP 2015506972A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hydrocortisone
- core
- composition according
- eudragit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 68
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 32
- 229920000642 polymer Polymers 0.000 claims 20
- 229960000890 hydrocortisone Drugs 0.000 claims 16
- 238000000034 method Methods 0.000 claims 11
- 230000003111 delayed effect Effects 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- 229940069328 povidone Drugs 0.000 claims 6
- 229920003139 Eudragit® L 100 Polymers 0.000 claims 5
- 229920003141 Eudragit® S 100 Polymers 0.000 claims 5
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical group CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 230000001919 adrenal effect Effects 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 239000004014 plasticizer Substances 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 3
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 208000020576 Adrenal disease Diseases 0.000 claims 1
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010056979 Colitis microscopic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000013020 final formulation Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000004341 lymphocytic colitis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 208000015124 ovarian disease Diseases 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920002959 polymer blend Polymers 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 229960000652 sertindole Drugs 0.000 claims 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1202433.7A GB201202433D0 (en) | 2012-02-13 | 2012-02-13 | Controlled drug release |
| GB1202433.7 | 2012-02-13 | ||
| US201261599704P | 2012-02-16 | 2012-02-16 | |
| US61/599,704 | 2012-02-16 | ||
| US201261600958P | 2012-02-20 | 2012-02-20 | |
| US61/600,958 | 2012-02-20 | ||
| PCT/GB2013/050311 WO2013121184A1 (en) | 2012-02-13 | 2013-02-12 | Hydrocortisone controlled release formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506972A JP2015506972A (ja) | 2015-03-05 |
| JP2015506972A5 true JP2015506972A5 (enExample) | 2016-04-07 |
| JP6293678B2 JP6293678B2 (ja) | 2018-03-14 |
Family
ID=45930017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556141A Active JP6293678B2 (ja) | 2012-02-13 | 2013-02-12 | ハイドロコーチゾンの制御放出製剤 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9750704B2 (enExample) |
| EP (1) | EP2814469B1 (enExample) |
| JP (1) | JP6293678B2 (enExample) |
| KR (1) | KR102023559B1 (enExample) |
| CN (2) | CN104105481A (enExample) |
| AU (1) | AU2013220139B2 (enExample) |
| BR (1) | BR112014020008B1 (enExample) |
| CA (1) | CA2864031C (enExample) |
| CY (1) | CY1123202T1 (enExample) |
| DK (1) | DK2814469T3 (enExample) |
| ES (1) | ES2792069T3 (enExample) |
| GB (2) | GB201202433D0 (enExample) |
| HK (1) | HK1203824A1 (enExample) |
| HR (1) | HRP20200780T1 (enExample) |
| HU (1) | HUE048904T2 (enExample) |
| IL (2) | IL234061B (enExample) |
| IN (1) | IN2014DN06808A (enExample) |
| LT (1) | LT2814469T (enExample) |
| ME (1) | ME03742B (enExample) |
| MX (1) | MX361407B (enExample) |
| NZ (2) | NZ627468A (enExample) |
| PL (1) | PL2814469T3 (enExample) |
| PT (1) | PT2814469T (enExample) |
| RS (1) | RS60346B1 (enExample) |
| RU (1) | RU2619869C2 (enExample) |
| SI (1) | SI2814469T1 (enExample) |
| SM (1) | SMT202000286T1 (enExample) |
| WO (1) | WO2013121184A1 (enExample) |
| ZA (1) | ZA201508728B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201202433D0 (en) | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
| WO2016196687A1 (en) * | 2015-06-01 | 2016-12-08 | Massachusetts Institute Of Technology | System and method for neuroendocrine control |
| FR3057775B1 (fr) * | 2016-10-26 | 2018-11-02 | Crossject | Solution pharmaceutique d’hydrocortisone pour dispositif d’injection |
| KR101982287B1 (ko) * | 2019-01-04 | 2019-05-24 | (주)청아굿푸드 | 천연 추출물 함유 서방성 제제 및 그 제조방법 |
| KR20230131916A (ko) | 2021-01-15 | 2023-09-14 | 갈벤타 아게 | 박동성 방출 카페인 제제 |
| US11904046B1 (en) | 2022-11-14 | 2024-02-20 | Eton Pharmaceuticals, Inc. | Hydrocortisone oral liquid formulations |
| WO2025240605A1 (en) | 2024-05-15 | 2025-11-20 | Neurocrine Biosciences, Inc. | Combination treatment |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6013711A (ja) * | 1983-06-21 | 1985-01-24 | ザ、プロクタ−、エンド、ギヤンブル、カンパニ− | コルチコステロイドを含有する浸透局所製薬組成物 |
| US4552872A (en) | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
| GB2292079B (en) * | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
| IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| US5686106A (en) | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
| KR19990077278A (ko) | 1996-01-16 | 1999-10-25 | 마이클 오코넬 | 약물의 하부 위장관으로의 국소적 전달 |
| DE19718012C1 (de) | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
| US6066339A (en) * | 1997-10-17 | 2000-05-23 | Elan Corporation, Plc | Oral morphine multiparticulate formulation |
| JP2004507487A (ja) * | 2000-08-29 | 2004-03-11 | メファ・アクチェンゲゼルシャフト | 腸疾患治療薬 |
| AP1748A (en) * | 2001-03-13 | 2007-06-11 | Penwest Pharmaceuticals Co | Chronotherapeutic dosage forms. |
| WO2003013476A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Compositions and methods to prevent abuse of opioids |
| GB0119848D0 (en) | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
| NZ532564A (en) | 2001-11-23 | 2006-06-30 | Procter & Gamble | Solid unit dosage forms for oral administration which minimise the impact of coating fractures especially for larger or heavier dosage forms |
| JP5371189B2 (ja) | 2003-09-15 | 2013-12-18 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症性腸疾患の治療のためのシクレソニドの使用 |
| GB0400031D0 (en) * | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| SI2049123T1 (sl) * | 2006-08-03 | 2013-04-30 | Horizon Pharma Ag | Zdravljenje revmatoznih bolezni z zadržanim sproščanjem glukokortikoida |
| WO2008059062A1 (en) | 2006-11-17 | 2008-05-22 | Da Volterra | Colonic delivery using zn/pectin beads with a eudragit coating. |
| EP2143424A4 (en) | 2007-03-26 | 2013-07-31 | Teikoku Seiyaku Kk | ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON |
| JP2011506607A (ja) * | 2007-12-17 | 2011-03-03 | ザリカス インコーポレイティッド | 免疫炎症性障害の処置のための治療法 |
| GB0817120D0 (en) * | 2008-09-19 | 2008-10-29 | Diurnal Ltd | Treatment of adrenal insufficiency |
| NZ582836A (en) | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
| WO2010113177A2 (en) | 2009-03-31 | 2010-10-07 | Reliance Life Sciences Pvt. Ltd. | Oral insulin delivery systems for controlling diabetes |
| NZ595428A (en) | 2009-04-07 | 2013-04-26 | Duocourt Pharma Ab | Improved glucocorticoid therapy |
| US9284416B2 (en) | 2009-11-16 | 2016-03-15 | Evonik Roehm Gmbh | Process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent |
| IT1405012B1 (it) * | 2010-08-06 | 2013-12-16 | Sofar Spa | Composizioni di beclometasone dipropionato in microsfere gastroresistenti a rilascio modificato e processo per il loro ottenimento |
| GB201202433D0 (en) | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
-
2012
- 2012-02-13 GB GBGB1202433.7A patent/GB201202433D0/en not_active Ceased
-
2013
- 2013-02-12 HU HUE13709499A patent/HUE048904T2/hu unknown
- 2013-02-12 RU RU2014130866A patent/RU2619869C2/ru active
- 2013-02-12 ES ES13709499T patent/ES2792069T3/es active Active
- 2013-02-12 AU AU2013220139A patent/AU2013220139B2/en active Active
- 2013-02-12 MX MX2014009716A patent/MX361407B/es active IP Right Grant
- 2013-02-12 PL PL13709499T patent/PL2814469T3/pl unknown
- 2013-02-12 NZ NZ627468A patent/NZ627468A/en unknown
- 2013-02-12 WO PCT/GB2013/050311 patent/WO2013121184A1/en not_active Ceased
- 2013-02-12 IN IN6808DEN2014 patent/IN2014DN06808A/en unknown
- 2013-02-12 RS RS20200578A patent/RS60346B1/sr unknown
- 2013-02-12 CN CN201380008921.6A patent/CN104105481A/zh active Pending
- 2013-02-12 EP EP13709499.1A patent/EP2814469B1/en active Active
- 2013-02-12 PT PT137094991T patent/PT2814469T/pt unknown
- 2013-02-12 ME MEP-2020-122A patent/ME03742B/me unknown
- 2013-02-12 SI SI201331723T patent/SI2814469T1/sl unknown
- 2013-02-12 LT LTEP13709499.1T patent/LT2814469T/lt unknown
- 2013-02-12 CA CA2864031A patent/CA2864031C/en active Active
- 2013-02-12 US US14/374,179 patent/US9750704B2/en active Active
- 2013-02-12 HR HRP20200780TT patent/HRP20200780T1/hr unknown
- 2013-02-12 DK DK13709499.1T patent/DK2814469T3/da active
- 2013-02-12 CN CN201910452557.1A patent/CN110141557A/zh active Pending
- 2013-02-12 GB GB1302406.2A patent/GB2502402B/en active Active
- 2013-02-12 HK HK15104320.6A patent/HK1203824A1/xx unknown
- 2013-02-12 NZ NZ715616A patent/NZ715616A/en unknown
- 2013-02-12 SM SM20200286T patent/SMT202000286T1/it unknown
- 2013-02-12 JP JP2014556141A patent/JP6293678B2/ja active Active
- 2013-02-12 BR BR112014020008-4A patent/BR112014020008B1/pt active IP Right Grant
- 2013-02-12 KR KR1020147025024A patent/KR102023559B1/ko active Active
-
2014
- 2014-08-11 IL IL234061A patent/IL234061B/en active IP Right Grant
-
2015
- 2015-11-30 ZA ZA2015/08728A patent/ZA201508728B/en unknown
-
2016
- 2016-05-09 IL IL245546A patent/IL245546A0/en unknown
-
2017
- 2017-07-05 US US15/641,650 patent/US10166194B2/en active Active
-
2020
- 2020-05-06 CY CY20201100418T patent/CY1123202T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506972A5 (enExample) | ||
| JP4615124B2 (ja) | 制御された作用物質放出性を有する被覆された医薬品形 | |
| CN102970983B (zh) | 耐受酒精的口服药物制剂 | |
| KR100735506B1 (ko) | 결장에서 방출시키기 위한 다층 약제학적 생성물 | |
| JP5607670B2 (ja) | 時限拍動性薬物送達システム | |
| Pearnchob et al. | Dry polymer powder coating and comparison with conventional liquid-based coatings for Eudragit® RS, ethylcellulose and shellac | |
| JP2017019858A5 (enExample) | ||
| JP2006514988A5 (enExample) | ||
| RU2014130866A (ru) | Композиция гидрокортизона с контролируемым высвобождением | |
| JP2007510676A (ja) | 作用物質放出に関して調節作用のある物質を含有する、多層の剤形 | |
| Yang et al. | Preparation of sustained release capsules by electrostatic dry powder coating, using traditional dip coating as reference | |
| Pearnchob et al. | Dry powder coating of pellets with micronized Eudragit® RS for extended drug release | |
| JP2008540419A5 (enExample) | ||
| JP2016517867A (ja) | タンパク質性サブコートを有する腸溶性の多微粒子組成物 | |
| KR20160115995A (ko) | 지속 방출 특성을 가지며 에탄올의 영향에 대한 저항성을 갖는 약제학적 또는 건강기능성 조성물 | |
| Szafran et al. | New spout-fluid bed apparatus for electrostatic coating of fine particles and encapsulation | |
| Albanez et al. | Enteric coating process of diclofenac sodium pellets in a fluid bed coater with a wurster insert: Influence of process variables on coating performance and release profile | |
| CN103919735B (zh) | 一种盐酸坦索罗辛缓释微丸及其制备方法 | |
| TWI508755B (zh) | 供三甲氧苄嗪（ｔｒｉｍｅｔａｚｉｄｉｎｅ）延長釋放之醫藥組合物 | |
| Kranz et al. | Evaluation of the drug release patterns and long term stability of aqueous and organic coated pellets by using blends of enteric and gastrointestinal insoluble polymers | |
| JP7374992B2 (ja) | 有効成分を遠位結腸で遅延放出する多層構造ペレット剤 | |
| WO2015085739A1 (zh) | 一种多层固体药物剂型 | |
| Fukumori et al. | Fluid bed processes for forming functional particles | |
| JP2017019880A5 (enExample) | ||
| Kim et al. | Optimization of tamsulosin hydrochloride controlled release pellets coated with Surelease and neutralized HPMCP |